Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for MapLight Therapeutics, Inc. (MPLT : NSDQ)

• Company Description    MapLight Therapeutics Inc. is a clinical-stage biopharmaceutical company. It focused on improving the lives of patients suffering from debilitating central nervous system disorders. The company's lead product candidate includes ML-007C-MA. MapLight Therapeutics Inc. is based in SAN FRANCISCO. Number of Employees: 133

• Price / Volume Information    Yesterday's Closing Price: $36.56 Daily Weekly Monthly 20 Day Moving Average: 514,771 shares Shares Outstanding: 42.62 (millions) Market Capitalization: $1,558.12 (millions) Beta: 52 Week High: $40.43 52 Week Low: $12.24 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 9.86% 9.00% 12 Week 19.09% 16.17% Year To Date 108.14% 92.23%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 800 Chesapeake Drive - Redwood City,CA 94063 USA ph: 617-984-6300 fax: - investors@maplightrx.com http://www.maplightrx.com

• General Corporate Information    Officers Christopher A. Kroeger - Chief Executive Officer Vishwas Setia - Chief Financial Officer Timothy Garnett - Director Nanna Luneborg - Director George Pavlov - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 56565P103 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/13/26 Share - Related Items Shares Outstanding: 42.62 Most Recent Split Date: (:1) Beta: Market Capitalization: $1,558.12 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-1.24 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-5.13 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 6.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/13/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 3.90 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -% vs. Previous Quarter: 45.75% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/26 - - 03/31/26 - - 12/31/25 - - ROA 06/30/26 - - 03/31/26 - - 12/31/25 - - Current Ratio 06/30/26 - - 03/31/26 - 22.91 12/31/25 - 20.01 Quick Ratio 06/30/26 - - 03/31/26 - 22.91 12/31/25 - 20.01 Operating Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Net Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Pre-Tax Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Book Value 06/30/26 - - 03/31/26 - 9.38 12/31/25 - 10.10 Inventory Turnover 06/30/26 - - 03/31/26 - - 12/31/25 - - Debt-to-Equity 06/30/26 - - 03/31/26 - 0.00 12/31/25 - 0.00 Debt-to-Capital 06/30/26 - - 03/31/26 - 0.00 12/31/25 - 0.00

Powered by Zacks Investment Research ©